Predict your next investment

Asset/Investment Management
aspirecapital.com

See what CB Insights has to offer

Investments

2

About Aspire Capital

Aspire Capital Fund is a Chicago-based, long-only investment fund focused on making open market and direct equity investments in publicly traded companies.

Aspire Capital Headquarter Location

155 North Wacker Drive Suite 1600

Chicago, Illinois, 60606,

United States

312-658-0400

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Aspire Capital News

X4 Pharmaceuticals : Termination of a Material Definitive Agreement - Form 8-K

Jan 14, 2022

01/14/2022 | 04:25pm EST Message : of the Securities Exchange Act of 1934 Date of Report (Data of earliest event reported): January 13, 2022 X4 PHARMACEUTICALS, INC. Delaware Boston, Massachusetts (Zip Code) (Registrant's telephone number, including area code) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ ☐ ☐ ☐ Securities registered pursuant to Section 12(b) of the Act: Title of each class XFOR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company ☒ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☒ Item 1.02 Termination of a Material Definitive Agreement On January 13, 2022, X4 Pharmaceuticals, Inc. (the "Company") delivered to Aspire Capital Fund, LLC, an Illinois limited liability company ("Aspire Capital"), a notice of termination terminating the Common Stock Purchase Agreement dated October 14, 2020 (the "Aspire Purchase Agreement") with Aspire Capital effective as of January 14, 2022. The Aspire Purchase Agreement provided that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital was committed to purchase up to an aggregate of $50 million of shares of the Company's common stock over the 36-monthterm of the Aspire Purchase Agreement at a price per share equal to (i) the lowest sale price of the Company's common stock on the purchase date or (ii) the arithmetic average of the three (3) lowest closing sale prices for the Company's common stock during the ten (10) consecutive trading days ending on the trading day immediately preceding the purchase date. On October 16, 2020, the Company filed with the Securities and Exchange Commission (the "SEC") a prospectus supplement and accompanying base prospectus registering up to $50 million of shares of common stock ("Aspire Prospectus") that may have been offered to Aspire Capital from time to time under the Aspire Purchase Agreement and pursuant to the Company's shelf registration statement on Form S-3 (File No. 333-242372), originallyfiled with the SEC on August 7, 2020 and declared effective by the SEC on August 19, 2020. From October 16, 2020 through the date of termination, the Company sold no shares of common stock under the Aspire Purchase Agreement. Upon termination, the Company has no further obligations under the Aspire Purchase Agreement and will make no sales pursuant to the Aspire Prospectus. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934 the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. X4 PHARMACEUTICALS, INC.

Aspire Capital Investments

2 Investments

Aspire Capital has made 2 investments. Their latest investment was in Ocean Power Technologies as part of their PIPE on October 10, 2019.

CBI Logo

Aspire Capital Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/25/2019

PIPE

Ocean Power Technologies

$10M

Yes

2

3/14/2019

PIPE - II

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/25/2019

3/14/2019

Round

PIPE

PIPE - II

Company

Ocean Power Technologies

Subscribe to see more

Amount

$10M

$99M

New?

Yes

Subscribe to see more

Co-Investors

Sources

2

10

Aspire Capital Team

1 Team Member

Aspire Capital has 1 team member, including current Founder, David A Fry.

Name

Work History

Title

Status

David A Fry

Founder

Current

Name

David A Fry

Work History

Title

Founder

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.